Removing Obstacles in Neuroscience Drug Discovery: The Future Path for Animal Models

Construct validity in psychological tests.

Cronbach, L. J., & Meehl, P. E. (1955) · Psychological Bulletin · doi:10.1037/h0040957 · Cited by 11,195 · see citing works

Can the pharmaceutical industry reduce attrition rates?

Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167 · see citing works

SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE

DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565 · see citing works

THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE

Schildkraut, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,499 · see citing works

Subanesthetic Effects of the Noncompetitive NMDA Antagonist, Ketamine, in Humans: Psychotomimetic, Perceptual, Cognitive, and Neuroendocrine Responses

Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · see citing works

The druggable genome

Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · see citing works

Behavioural despair in rats: A new model sensitive to antidepressant treatments

Porsolt, R. D., Anton, G., Blavet, N., & Jalfre, M. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90118-8 · Cited by 3,138 · see citing works

International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin).

Hoyer, D., Clarke, D. E., Fozard, J. R., Hartig, P. R., Martin, G. R., Mylecharane, E. J., Saxena, P. R., & Humphrey, P. P. A. (1994) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)06783-3 · Cited by 2,997 · see citing works

Psychopharmacology: The Fourth Generation of Progress

Bloom, F. E., & Kupfer, D. J. (1995) · Medical Entomology and Zoology · Cited by 2,985 · see citing works

Recent advances in the phencyclidine model of schizophrenia

(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · see citing works

The use of a plus-maze to measure anxiety in the mouse

Lister, R. G. (1987) · Psychopharmacology · doi:10.1007/bf00177912 · Cited by 2,617 · see citing works

Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs

Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220 · see citing works

Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia.

Perry, E., Tomlinson, B. E., Blessed, G., Bergmann, K., Gibson, P., & Perry, R. H. (1978) · British medical journal · doi:10.1136/bmj.2.6150.1457 · Cited by 2,043 · see citing works

Efficacy of Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Jorenby, D. E. (2006) · JAMA · doi:10.1001/jama.296.1.56 · Cited by 1,635 · see citing works

Chronic Mild Stress (CMS) Revisited: Consistency and Behavioural-Neurobiological Concordance in the Effects of CMS

Willner, P. (2005) · Neuropsychobiology · doi:10.1159/000087097 · Cited by 1,605 · see citing works

Assessing antidepressant activity in rodents: recent developments and future needs

Cryan, J. F., Markou, A., & Lucki, I. (2002) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)02017-5 · Cited by 1,551 · cited 2× · see citing works

Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review

Geyer, M. A., Krebs-Thomson, K., Braff, D. L., & Swerdlow, N. R. (2001) · Psychopharmacology · doi:10.1007/s002130100811 · Cited by 1,484 · see citing works

Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies

Crawley, J. N., Belknap, J. K., Collins, A. C., Crabbe, J. C., Frankel, W. N., Henderson, N. D., HITZEMANN, R. J., Maxson, S. C., Miner, L. L., Silva, A. J., et al. (1997) · Psychopharmacology · doi:10.1007/s002130050327 · Cited by 1,372 · see citing works

Varenicline, an α4β2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Sustained-Release Bupropion and Placebo for Smoking Cessation<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>

Gonzales, D. (2006) · JAMA · doi:10.1001/jama.296.1.47 · Cited by 1,361 · see citing works

Identification of separable cognitive factors in schizophrenia

Nuechterlein, K. H., Barch, D. M., Gold, J. M., Goldberg, T. E., Green, M. F., & Heaton, R. K. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.007 · Cited by 1,304 · see citing works

APRIORITY

Asher, R. (1961) · The Lancet · doi:10.1016/s0140-6736(61)91217-x · Cited by 1,290 · see citing works

The Biochemistry of Affective Disorders

Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230 · see citing works

Norepinephrine in Depressive Reactions

Bunney, W. E. (1965) · Archives of General Psychiatry · doi:10.1001/archpsyc.1965.01730060001001 · Cited by 1,154 · see citing works

Psychopharmacology: The Fourth Generation of Progress

Green, A. I. (1996) · Psychiatric Services · doi:10.1176/ps.47.3.312 · Cited by 1,151 · see citing works

Imaging β-amyloid burden in aging and dementia

Rowe, C. C., Ng, S., Ackermann, U., Gong, S. J., Pike, K., Savage, G., Cowie, T. F., Dickinson, K. L., Maruff, P., Darby, D., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000261919.22630.ea · Cited by 1,104 · see citing works

Neuropsychopharmacology: The Fifth Generation of Progress

Sagduyu, K. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.7.1251-a · Cited by 1,023 · see citing works

Ethological and temporal analyses of anxiety-like behavior: The elevated plus-maze model 20 years on

Carobrez, A. P., & Bertoglio, L. J. (2005) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2005.04.017 · Cited by 993 · see citing works

Study of a New Schizophrenomimetic Drug—Sernyl

LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921 · see citing works

Drugs, their targets and the nature and number of drug targets

Imming, P., Sinning, C., & Meyer, A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2132 · Cited by 840 · see citing works

Clinical biomarkers in drug discovery and development

Frank, R. A., & Hargreaves, R. J. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1130 · Cited by 794 · see citing works

Neurobiological similarities in depression and drug dependence: a self-medication hypothesis

Markou, A. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00113-9 · Cited by 767 · see citing works

Exploratory behavior models of anxiety in mice

Crawley, J. N. (1985) · Neuroscience & Biobehavioral Reviews · doi:10.1016/0149-7634(85)90030-2 · Cited by 756 · see citing works

Neuropsychopharmacology : The Fifth Generation of Progress

Davis, K. L., Charney, D. S., Coyle, J. T., & Nemeroff, C. B. (2002) · Lippincott Williams & Wilkins eBooks · Cited by 747 · see citing works

Ketamine-Induced Exacerbation of Psychotic Symptoms and Cognitive Impairment in Neuroleptic-Free Schizophrenics

Malhotra, A. K. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00036-5 · Cited by 681 · see citing works

NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers

Malhotra, A. K. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680 · see citing works

Animal models of Alzheimer's disease and frontotemporal dementia

Götz, J., & Ittner, L. M. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2420 · Cited by 676 · see citing works

Memory and cognitive function in man

Drachman, D. A. (1977) · Neurology · doi:10.1212/wnl.27.8.783 · Cited by 619 · see citing works

Neurochemical Modulation of Response Inhibition and Probabilistic Learning in Humans

Chamberlain, S. R., Müller, U., Blackwell, A. D., Clark, L., Robbins, T. W., & Sahakian, B. J. (2006) · Science · doi:10.1126/science.1121218 · Cited by 573 · see citing works

Use of the elevated plus maze in the search for novel anxiolytic agents

Dawson, G. R., & Tricklebank, M. D. (1995) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)88973-7 · Cited by 563 · see citing works

Animal models of drug craving

Markou, A., Weiss, F., Gold, L. H., Caine, S. B., Schulteis, G., & Koob, G. F. (1993) · Psychopharmacology · doi:10.1007/bf02244907 · Cited by 551 · see citing works

Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid

Rollema, H., Chambers, L. K., Coe, J. W., Glowa, J., Hurst, R. S., Lebel, L. A., Lu, Y., Mansbach, R. S., Mather, R. J., Rovetti, C. C., et al. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.10.016 · Cited by 533 · see citing works

Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia

D, A. O. M., Harris, J. G., Johnson, L. L., Pender, V., Kongs, S., Allensworth, D., Ellis, J., Zerbe, G. O., Leonard, S. S., Stevens, K. E., et al. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.630 · Cited by 530 · see citing works

Target-based drug discovery: is something wrong?

Sams‐Dodd, F. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03316-1 · Cited by 522 · see citing works

Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study

Edison, P., Archer, H. A., Hinz, R., Hammers, A., Pavese, N., Tai, Y. F., Hotton, G., Cutler, D., Fox, N., Kennedy, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000244749.20056.d4 · Cited by 518 · see citing works

Dopamine: 50 years in perspective

Iversen, S. D., & Iversen, L. L. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.002 · Cited by 514 · see citing works

Psychiatric endophenotypes and the development of valid animal models

Gould, T. D., & Gottesman, I. I. (2005) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2005.00186.x · Cited by 507 · see citing works

Functions of frontostriatal systems in cognition: comparative neuropsychopharmacological studies in rats, monkeys and humans

Chudasama, Y., & Robbins, T. W. (2006) · Biological Psychology · doi:10.1016/j.biopsycho.2006.01.005 · Cited by 484 · see citing works

Behavioral phenotyping strategies for mutant mice

Crawley, J. N. (2008) · Neuron · doi:10.1016/j.neuron.2008.03.001 · Cited by 439 · see citing works

Factors controlling measures of anxiety and responses to novelty in the mouse

File, S. E. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00292-3 · Cited by 437 · see citing works

Ketamine activates psychosis and alters limbic blood flow in schizophrenia

Lahti, A. C., Holcomb, H. H., Medoff, D. R., & Tamminga, C. A. (1995) · Neuroreport · doi:10.1097/00001756-199504190-00011 · Cited by 434 · see citing works

Dopamine D4 Receptor-Knock-Out Mice Exhibit Reduced Exploration of Novel Stimuli

Dulawa, S. C., Grandy, D. K., Low, M. J., Paulus, M. P., & Geyer, M. A. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-21-09550.1999 · Cited by 432 · see citing works

Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials

Gruttola, V. D., Clax, P. A., DeMets, D. L., Downing, G. J., Ellenberg, S. S., Friedman, L., Gail, M. H., Prentice, R. L., Wittes, J., & Zeger, S. L. (2001) · Controlled Clinical Trials · doi:10.1016/s0197-2456(01)00153-2 · Cited by 428 · see citing works

The Discovery of Fluoxetine Hydrochloride (Prozac)

Wong, D. T., Perry, K. W., & Bymaster, F. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1821 · Cited by 419 · see citing works

Measurement and Treatment Research to Improve Cognition in Schizophrenia: NIMH MATRICS initiative to support the development of agents for improving cognition in schizophrenia

Marder, S. R., & Fenton, W. S. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.09.010 · Cited by 419 · see citing works

Genetic Theorizing and Schizophrenia

Gottesman, I. I., & Shields, J. (1973) · The British Journal of Psychiatry · doi:10.1192/bjp.122.1.15 · Cited by 413 · see citing works

Rationale, pharmacology and clinical efficacy of partial agonists of α4β2 nACh receptors for smoking cessation

Rollema, H., Coe, J. W., Chambers, L. K., Hurst, R. S., Stahl, S. M., & Williams, K. E. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.05.003 · Cited by 400 · see citing works

Neurometabolic coupling in cerebral cortex reflects synaptic more than spiking activity

Viswanathan, A., & Freeman, R. D. (2007) · Nature Neuroscience · doi:10.1038/nn1977 · Cited by 397 · see citing works

Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat

Robinson, E. S. J., Eagle, D. M., Mar, A. C., Bari, A., Banerjee, G., Jiang, X., Dalley, J. W., & Robbins, T. W. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301487 · Cited by 359 · see citing works

P50 sensory gating ratios in schizophrenics and controls: A review and data analysis

Patterson, J. V., Hetrick, W. P., Boutros, N. N., Jin, Y., Sandman, C. A., Stern, H. S., Potkin, S. G., & Bunney, W. E. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2007.02.009 · Cited by 352 · see citing works

Human and animal cognition: Continuity and discontinuity

Premack, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706147104 · Cited by 350 · see citing works

Do animal models of anxiety predict anxiolytic-like effects of antidepressants?

Borsini, F., Podhorna, J., & Marazziti, D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1155-6 · Cited by 347 · see citing works

Neurophysiological biomarkers for drug development in schizophrenia

Javitt, D. C., Spencer, K., Thaker, G. K., Winterer, G., & Hajós, M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2463 · Cited by 340 · see citing works

Animal models of psychiatric disorders

Koob, G. F., & Zimmer, A. (2012) · Handbook of clinical neurology · doi:10.1016/b978-0-444-52002-9.00009-7 · Cited by 337 · see citing works

Drug development for CNS disorders: strategies for balancing risk and reducing attrition

Pangalos, M. N., Schechter, L. E., & Hurko, O. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2094 · Cited by 334 · see citing works

Target discovery

Lindsay, M. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1202 · Cited by 333 · see citing works

EFFECT OF DRUGS ON THE UPTAKE, RELEASE, AND METABOLISM OF H3-NOREPINEPHRINE IN THE RAT BRAIN

Glowinski, J., & Axelrod, J. (1965) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)27077-x · Cited by 331 · see citing works

Modeling madness in mice: one piece at a time

Arguello, P. A., & Gogos, J. A. (2006) · Neuron · doi:10.1016/j.neuron.2006.09.023 · Cited by 309 · see citing works

Acute and chronic effects of ketamine upon human memory: a review

Morgan, C. J. A., & Curran, H. V. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0572-3 · Cited by 304 · see citing works

Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative.

Carter, C., & Barch, D. (2007) · Schizophrenia bulletin · doi:10.1093/schbul/sbm081 · Cited by 296 · see citing works

A decade of modeling Alzheimer's disease in transgenic mice

MCGOWAN, E., ERIKSEN, J., & HUTTON, M. (2006) · Trends in Genetics · doi:10.1016/j.tig.2006.03.007 · Cited by 287 · see citing works

What Are the Right Targets for Psychopharmacology?

Hyman, S. E., & Fenton, W. S. (2003) · Science · doi:10.1126/science.1077141 · Cited by 282 · see citing works

The State of Innovation in Drug Development

Kola, I. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100479 · Cited by 276 · see citing works

Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy

Götz, J., Streffer, J. R., David, D. C., Schild, A., Hoerndli, F. J., Pennanen, L., Kurosinski, P., & Chen, F. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001508 · Cited by 272 · see citing works

Neuronal Systems Underlying Behaviors Related to Nicotine Addiction: Neural Circuits and Molecular Genetics

Picciotto, M. R., & Corrigall, W. A. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-09-03338.2002 · Cited by 261 · see citing works

Encyclopedia of Sensors

Grimes, C. A., Dickey, E. C., Pishko, M. V., & Marcus, R. A. (2006) · Cited by 256 · see citing works

Virtual drug discovery and development for neglected diseases through public–private partnerships

Nwaka, S., & Ridley, R. G. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1230 · Cited by 255 · see citing works

Inhibitory Control in Rats Performing a Stop-Signal Reaction-Time Task: Effects of Lesions of the Medial Striatum and d-Amphetamine.

Eagle, D. M., & Robbins, T. W. (2003) · Behavioral Neuroscience · doi:10.1037/0735-7044.117.6.1302 · Cited by 252 · see citing works

Modern biomedical research: an internally self-consistent universe with little contact with medical reality?

Horrobin, D. F. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1012 · Cited by 248 · see citing works

Neurotransmitter transporters and their impact on the development of psychopharmacology

Iversen, L. L. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706428 · Cited by 243 · see citing works

Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.

Javitt, D. (1987) · PubMed · Cited by 240 · see citing works

Early experience as a determinant of adult behavioural responses to reward: the effects of repeated maternal separation in the rat

Matthews, K., & Robbins, T. W. (2003) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(03)00008-3 · Cited by 231 · see citing works

The medical benefit of 5-HT research

Jones, B. J., & Blackburn, T. P. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00745-6 · Cited by 227 · see citing works

Drug discovery in dementia: the role of rodent models

Dam, D. V., & Deyn, P. P. D. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2075 · Cited by 220 · see citing works

Neuronal nicotinic receptors: A perspective on two decades of drug discovery research

Arneric, S. P., Holladay, M., & Williams, M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.033 · Cited by 208 · see citing works

The excitatory amino acid antagonist d-CPP-ene (SDZ EAA-494) in patients with epilepsy

Sveinbjörnsdóttir, S., Sander, J. W. A. S., Upton, D., Thompson, P. J., Patsalos, P. N., Hirt, D., Emre, M., Lowe, D., & Duncan, J. S. (1993) · Epilepsy Research · doi:10.1016/0920-1211(93)90031-2 · Cited by 200 · see citing works

Targeted gene mutation approaches to the study of anxiety-like behavior in mice

Holmes, A. (2001) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00012-4 · Cited by 198 · see citing works

Animal models for the negative symptoms of schizophrenia

Ellenbroek, B. A., & Cools, A. R. (2000) · Behavioural Pharmacology · doi:10.1097/00008877-200006000-00006 · Cited by 198 · see citing works

Biological psychiatry

Caruncho, H. J. (2002) · Journal of Chemical Neuroanatomy · doi:10.1016/s0891-0618(02)00002-9 · Cited by 197 · see citing works

Drug Development: The role of innovation in drug development

Drews, J., & Ryser, S. (1997) · Nature Biotechnology · doi:10.1038/nbt1297-1318 · Cited by 179 · see citing works

Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs

Gallhofer, B., Bauer, U., Lis, S., Krieger, S., & Gruppe, H. (1996) · European Neuropsychopharmacology · doi:10.1016/0924-977x(96)00010-7 · Cited by 177 · see citing works

Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative

Carter, C. S., Barch, D. M., Buchanan, R. W., Bullmore, E. T., Krystal, J. H., Cohen, J. D., Geyer, M. A., Green, M. M., Nuechterlein, K. H., Robbins, T. W., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.03.020 · Cited by 174 · see citing works

Acute and Chronic Effects of Gepirone and Fluoxetine in Rats Tested in the Elevated Plus-maze

Silva, R. C. B., & Brandão, M. L. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00193-8 · Cited by 170 · see citing works

Fluoxetine Combined with a Serotonin-1A Receptor Antagonist Reversed Reward Deficits Observed during Nicotine and Amphetamine Withdrawal in Rats

Harrison, A. A. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00237-2 · Cited by 167 · see citing works

The family of sensorimotor gating disorders: Comorbidities or diagnostic overlaps?

Geyer, M. A. (2006) · Neurotoxicity Research · doi:10.1007/bf03033358 · Cited by 159 · see citing works

Cellular Plasticity Cascades: Genes-To-Behavior Pathways in Animal Models of Bipolar Disorder

Einat, H., & Manji, H. K. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.004 · Cited by 154 · see citing works

The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines

Millan, M. J., & Brocco, M. (2003) · European Journal of Pharmacology · doi:10.1016/s0014-2999(03)01275-5 · Cited by 149 · see citing works

The mGluR5 antagonist MPEP, but not the mGluR2/3 agonist LY314582, augments PCP effects on prepulse inhibition and locomotor activity

Henry, S. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00332-5 · Cited by 145 · see citing works

Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats

Bruijnzeel, A. W., & Markou, A. (2003) · Synapse · doi:10.1002/syn.10242 · Cited by 143 · see citing works

Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease.

Newberg, A. B., Wintering, N., Plößl, K., Hochold, J., Stabin, M. G., Watson, M., Skovronsky, D., Clark, C. M., Kung, M., & Kung, H. F. (2006) · PubMed · Cited by 143 · see citing works

Finding the target after screening the phenotype

Hart, C. P. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03415-x · Cited by 129 · see citing works

Cognitive Function in Schizophrenia— Do Neuroleptics Make a Difference?

Mortimer, A. M. (1997) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(96)00425-x · Cited by 129 · see citing works

Clinical and biochemical aspects of depressive disorders: II. Transmitter/receptor theories

Caldecott-Hazard, S., Morgan, D., DeLeon-Jones, F. A., Overstreet, D. H., & Janowsky, D. S. (1991) · Synapse · doi:10.1002/syn.890090404 · Cited by 124 · see citing works

A reverse-translational approach to bipolar disorder: Rodent and human studies in the Behavioral Pattern Monitor

Young, J. W., Minassian, A., Paulus, M. P., Geyer, M. A., & Perry, W. (2007) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2007.05.009 · Cited by 122 · see citing works

Ethological comparison of the effects of diazepam and acute/chronic imipramine on the behaviour of mice in the elevated plus-maze

Cole, J. C., & Rodgers, R. J. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00163-q · Cited by 120 · see citing works

Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats

Amitai, N., Semenova, S., & Markou, A. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0808-x · Cited by 118 · see citing works

Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine

Cartmell, J., Monn, J. A., & Schoepp, D. D. (2000) · Psychopharmacology · doi:10.1007/s002130050072 · Cited by 117 · see citing works

Classification of Anxiety and Depressive disorders: problems and solutions

Andrews, G., Anderson, T. M., Slade, T. N., & Sunderland, M. (2008) · Depression and Anxiety · doi:10.1002/da.20489 · Cited by 104 · see citing works

The Phencyclidine-Glutamate Model of Schizophrenia

Halberstadt, A. L. (1995) · Clinical Neuropharmacology · doi:10.1097/00002826-199506000-00004 · Cited by 104 · see citing works

Acute Ketamine Administration Alters the Brain Responses to Executive Demands in a Verbal Working Memory Task: an fMRI Study

Honey, R. A. E., Honey, G. D., O'Loughlin, C., Sharar, S. R., Kumaran, D., Bullmore, E. T., Menon, D. K., Donovan, T., Lupson, V., Bisbrown-Chippendale, R., et al. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300438 · Cited by 102 · see citing works

Serotonin and its place in the pathogenesis of depression.

Coppen, A. J., & Doogan, D. P. (1988) · PubMed · Cited by 102 · see citing works

Summary of a National Institute of Mental Health workshop: developing animal models of anxiety disorders

Shekhar, A., McCann, U., Meaney, M. J., Blanchard, D. C., Davis, M., Frey, K. A., Liberzon, I., Overall, K. L., Shear, M., Tecott, L. H., et al. (2001) · Psychopharmacology · doi:10.1007/s002130100859 · Cited by 101 · see citing works

Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer?

Tan, H.-Y., Callicott, J. H., & Weinberger, D. R. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002145 · Cited by 100 · see citing works

Advances in endophenotyping schizophrenia

BRAFF, D. L., Greenwood, T. A., Swerdlow, N. R., Light, G. A., & Schork, N. J. (2008) · World Psychiatry · doi:10.1002/j.2051-5545.2008.tb00140.x · Cited by 97 · see citing works

Neuropharmacology of 5‐hydroxytryptamine

Green, A. R. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706427 · Cited by 97 · see citing works

Keynote review: Is declining innovation in the pharmaceutical industry a myth?

Schmid, E. F., & Smith, D. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03524-5 · Cited by 96 · see citing works

Developing Predictive Animal Models and Establishing a Preclinical Trials Network for Assessing Treatment Effects on Cognition in Schizophrenia

Floresco, S. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi041 · Cited by 95 · see citing works

The Effects of Sertraline and Fluoxetine on Anxiety in the Elevated Plus-Maze Test

Kurt, M., Arik, A. C., & S. Çelik (2000) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp.2000.11.2.173 · Cited by 91 · see citing works

The ultimate model organism: progress in experimental medicine

Littman, B. H., & Williams, S. A. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1800 · Cited by 89 · see citing works

Neuroadaptations to chronic exposure to drugs of abuse: Relevance to depressive symptomatology seen across psychiatric diagnostic categories

Markou, A., & Kenny, P. J. (2002) · Neurotoxicity Research · doi:10.1080/10298420290023963 · Cited by 87 · see citing works

Opportunities and Challenges of Psychiatric Drug Discovery: Roles for Scientists in Academic, Industry, and Government Settings

Conn, P. J., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301638 · Cited by 86 · see citing works

Animal models and treatments for addiction and depression co-morbidity

Paterson, N. E., & Markou, A. (2007) · Neurotoxicity Research · doi:10.1007/bf03033479 · Cited by 84 · see citing works

Advanced behavioural screening: automated home cage ethology

Spruijt, B. M., & de Visser, L. (2006) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2006.06.010 · Cited by 84 · see citing works

Do we need any more new antiepileptic drugs?

Brodie, M. J. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00203-0 · Cited by 82 · see citing works

Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell

Paterson, N. E., Balfour, D. J. K., & Markou, A. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2007.05546.x · Cited by 80 · see citing works

Structural genomics and drug discovery

Lundstrom, K. H. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00028.x · Cited by 80 · see citing works

A collaborative knowledge base for cognitive phenomics

Sabb, F. W., Bearden, C. E., Glahn, D. C., Parker, D. S., Freimer, N. B., & Bilder, R. M. (2008) · Molecular Psychiatry · doi:10.1038/sj.mp.4002124 · Cited by 76 · see citing works

Anxiogenic-like effect of acute and chronic fluoxetine on rats tested on the elevated plus-maze

Silva, M. T. A., Alves, C. R., & Santarem, É. M. M. (1999) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x1999000300014 · Cited by 74 · see citing works

A pathophysiological paradigm for the therapy of psychiatric disease

Spedding, M., Jay, T. M., Silva, J. C. E., & Perret, L. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1753 · Cited by 73 · see citing works

Are cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?

Geyer, M. A. (2006) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2006.8.1/mgeyer · Cited by 72 · see citing works

Serotonergic Manipulations Both Potentiate and Reduce Brain Stimulation Reward in Rats: Involvement of Serotonin-1A Receptors

Harrison, A. A., & Markou, A. (2001) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29542-2 · Cited by 71 · see citing works

Factors affecting the hippocampal BOLD response during spatial memory

Shipman, S. L., & Astur, R. S. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.10.014 · Cited by 69 · see citing works

Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis

Enomoto, T., Noda, Y., & NABESHIMA, T. (2007) · Methods and Findings in Experimental and Clinical Pharmacology · doi:10.1358/mf.2007.29.4.1075358 · Cited by 65 · see citing works

Presynaptic Receptors for Dopamine, Histamine, and Serotonin

Feuerstein, T. J. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-74805-2_10 · Cited by 62 · see citing works

Preclinical research into cognition enhancers

Sarter, M. F. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.09.004 · Cited by 56 · see citing works

Biomarkers in Psychiatry: Methodological Issues

KRAEMER, H. C., Schultz, S. K., & Arndt, S. V. (2002) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200211000-00004 · Cited by 53 · see citing works

Corticotropin-Releasing Factor Receptor Antagonists in Affective Disorders and Drug Dependence - An Update

Dautzenberg, F. M., & Steckler, T. (2006) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152706776359619 · Cited by 49 · see citing works

Refinement of diagnosis and disease classification in psychiatry

Lecrubier, Y. (2008) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-007-1003-0 · Cited by 47 · see citing works

Translational research in the pharmaceutical industry: from bench to bedside

O’Connell, D. P., & Roblin, D. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.07.009 · Cited by 46 · see citing works

Animal Models of Psychopathology

Mineka, S., & Zinbarg, R. E. (1991) · Springer eBooks · doi:10.1007/978-1-4757-9715-2_3 · Cited by 44 · see citing works

The early history of psychotherapeutic drugs

Jacobsen, E. (1986) · Psychopharmacology · doi:10.1007/bf00310617 · Cited by 42 · see citing works

New developments in animal models of Alzheimer’s disease

Janus, C., Phinney, A. L., Chishti, M. A., & Westaway, D. A. (2001) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-001-0105-8 · Cited by 40 · see citing works

The role of pharmacological profiling in safety assessment

Williams, P. D. (1990) · Regulatory Toxicology and Pharmacology · doi:10.1016/s0273-2300(05)80061-3 · Cited by 39 · see citing works

Metabotropic glutamate receptor modulation, translational methods, and biomarkers: relationships with anxiety

Nordquist, R. E., Steckler, T., Wettstein, J. G., Mackie, C. E., & Spooren, W. P. J. M. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1096-9 · Cited by 38 · see citing works

Combining drug–disease and economic modelling to inform drug development decisions

Poland, B., & Wada, R. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02014-1 · Cited by 34 · see citing works

Breaking the log-jam in treatment development for cognition in schizophrenia: NIMH perspective

Fenton, W. S., Stover, E. L., & Insel, T. R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1564-1 · Cited by 33 · see citing works

New Approaches to Measurement and Treatment Research to Improve Cognition in Schizophrenia

Geyer, M. A. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi057 · Cited by 33 · see citing works

Paroxetine combined with a 5-HT1A receptor antagonist reversed reward deficits observed during amphetamine withdrawal in rats

Markou, A., Harrison, A. A., Chevrette, J., & Hoyer, D. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2008-2 · Cited by 30 · see citing works

Serotonin mechanisms in animal models of anxiety.

Sl, H., & McBlane, J. W. (1993) · PubMed · Cited by 29 · see citing works

Novel Multifunctional Anti-Alzheimer Drugs with Various CNS Neurotransmitter Targets and Neuroprotective Moieties

der Schyf, C. V., Mandel, S. A., Geldenhuys, W. J., Amit, T., Avramovich‐Tirosh, Y., Zheng, H., Fridkin, M., Gal, S., Weinreb, O., Am, O., et al. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018226 · Cited by 28 · see citing works

Toxicity of β‐amyloid vaccination in patients with Alzheimer's disease

Imbimbo, B. P. (2002) · Annals of Neurology · doi:10.1002/ana.10218 · Cited by 26 · see citing works

Psychobiological foundations of clinical psychiatry

Judd, L. L., & Groves, P. M. (1986) · Medical Entomology and Zoology · Cited by 23 · see citing works

Translational research in the pharmaceutical industry: from theory to reality

Sultana, S. R., Roblin, D., & OCONNELL, D. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.03.009 · Cited by 23 · see citing works

Developing Novel Anxiolytics: Improving Preclinical Detection and Clinical Assessment

Steckler, T., Stein, M. B., & Holmes, A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00005-9 · Cited by 19 · see citing works

Editorial

Tallman, J. F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00104-3 · Cited by 18 · see citing works

The antipsychotic potential of subtype-selective 5-HT receptor ligands based on interactions with mesolimbic dopamine systems

Tricklebank, M. D. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00064-2 · Cited by 18 · see citing works

PREFACE: What Do You Mean by “Translational Research”? An Enquiry Through Animal and Translational Models for CNS Drug Discovery: Psychiatric Disorders

McArthur, R. A., & Borsini, F. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373861-5.00032-1 · Cited by 13 · see citing works

Prospects of treating neurological diseases by gene therapy.

Lundstrom, K. H. (2007) · PubMed · Cited by 11 · see citing works

Nicotinic Receptors and the Treatment of Attentional and Cognitive Deficits in Neuropsychiatric Disorders: Focus on the α7 Nicotinic Acetylcholine Receptor as a Promising Drug Target for Schizophrenia

Chiamulera, C., & Fumagalli, G. F. (2007) · Central Nervous System Agents in Medicinal Chemistry · doi:10.2174/187152407783220797 · Cited by 10 · see citing works

Relationship between the development of behavioral tolerance and the biodisposition of phencyclidine in mice

Freeman, A. S., Martin, B. R., & Balster, R. L. (1984) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(84)90273-9 · Cited by 10 · see citing works

Erice statement on drug innovation

(2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.03033.x · Cited by 9 · see citing works

Involving the pharmaceutical and biotech communities in medication development for substance abuse

Gorodetzky, C. W., & Grudzinskas, C. V. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.06.012 · Cited by 7 · see citing works

Erratum: Opportunities and Challenges of Psychiatric Drug Discovery: Roles for Scientists in Academic, Industry, and Government Settings

Conn, P. J., & Roth, B. L. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.83 · Cited by 3 · see citing works

Erratum: Novel Drugs and Therapeutic Targets for Severe Mood Disorders

Mathew, S. J., Manji, H. K., & Charney, D. S. (2008) · Neuropsychopharmacology · doi:10.1038/npp.2008.84 · Cited by 2 · see citing works

Animal Models of Cognitive Disorders

Steckler, T. (2002) · Biological Psychiatry · doi:10.1002/0470854871.chxv1 · Cited by 1 · see citing works

An anatomically comprehensive atlas of the adult human brain transcriptome

Hawrylycz, M. J., Lein, E. S., Guillozet-Bongaarts, A. L., Shen, E. H., Ng, L., Miller, J. A., van de Lagemaat, L. N., Smith, K. A., Ebbert, A., Riley, Z. L., et al. (2012) · Nature · doi:10.1038/nature11405 · Cited by 3,083 · see citing works

Animal models of neuropsychiatric disorders

Nestler, E. J., & Hyman, S. E. (2010) · Nature Neuroscience · doi:10.1038/nn.2647 · Cited by 2,023 · see citing works

Conserved cell types with divergent features in human versus mouse cortex

Hodge, R. D., Bakken, T. E., Miller, J. A., Smith, K. A., Barkan, E. R., Graybuck, L. T., Close, J. L., Long, B., Johansen, N., Penn, O., et al. (2019) · Nature · doi:10.1038/s41586-019-1506-7 · Cited by 1,775 · see citing works

Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy

Millan, M. J., Agid, Y., Brüne, M., Bullmore, E. T., Carter, C. S., Clayton, N. S., Connor, R., Davis, S., Deakin, B., DeRubeis, R. J., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3628 · Cited by 1,292 · see citing works

The neurobiology of anhedonia and other reward-related deficits

Der-Avakian, A., & Markou, A. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.005 · Cited by 1,130 · see citing works

Animal models of human disease: challenges in enabling translation

McGonigle, P., & Ruggeri, B. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.08.006 · Cited by 610 · see citing works

The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis

Scofield, M. D., Heinsbroek, J. A., Gipson, C. D., Kupchik, Y. M., Spencer, S., Smith, A. C. W., Roberts-Wolfe, D., & Kalivas, P. W. (2016) · Pharmacological Reviews · doi:10.1124/pr.116.012484 · Cited by 598 · see citing works

Water associated zero maze: a novel rat test for long term traumatic re-experiencing

Ritov, G., & Richter‐Levin, G. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00001 · Cited by 579 · see citing works

Measuring thigmotaxis in larval zebrafish

Schnörr, S. J., Steenbergen, P. J., Richardson, M. K., & Champagne, D. L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.016 · Cited by 471 · see citing works

Schizophrenia, “Just the Facts” 5. Treatment and prevention Past, present, and future

Tandon, R., Nasrallah, H. A., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.05.025 · Cited by 385 · see citing works

Translating rodent behavioral repertoire to zebrafish (Danio rerio): Relevance for stress research

Champagne, D. L., Hoefnagels, C. C. M., de Kloet, E. R., & Richardson, M. K. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.06.001 · Cited by 381 · see citing works

The age of anxiety: role of animal models of anxiolytic action in drug discovery

Cryan, J. F., & Sweeney, F. F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01362.x · Cited by 313 · see citing works

Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia

Young, J., Powell, S., Risbrough, V., Marston, H., & Geyer, M. (2009) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2009.02.004 · Cited by 315 · see citing works

Spontaneous Gamma Activity in Schizophrenia

Hirano, Y., Oribe, N., Kanba, S., Onitsuka, T., Nestor, P. G., & Spencer, K. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2642 · Cited by 263 · see citing works

The touchscreen operant platform for assessing executive function in rats and mice

Mar, A. C., Horner, A. E., Nilsson, S. R. O., Alsiö, J., Kent, B. A., Kim, C. H., Holmes, A., Saksida, L. M., & Bussey, T. J. (2013) · Nature Protocols · doi:10.1038/nprot.2013.123 · Cited by 259 · see citing works

Helplessness: a systematic translational review of theory and evidence for its relevance to understanding and treating depression.

Pryce, C., Azzinnari, D., Spinelli, S., Seifritz, E., Tegethoff, M., & Meinlschmidt, G. (2011) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2011.06.006 · Cited by 227 · see citing works

Methamphetamine-Associated Psychosis

Grant, K. M., LeVan, T. D., Wells, S. M., Li, M., Stoltenberg, S. F., Gendelman, H. E., Carlo, G., & Bevins, R. A. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9288-1 · Cited by 231 · see citing works

3D in vitro modeling of the central nervous system

Hopkins, A. M., DeSimone, E. K., Chwalek, K., & Kaplan, D. L. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2014.11.003 · Cited by 230 · see citing works

Patterns of avoidance behaviours in the light/dark preference test in young juvenile zebrafish: A pharmacological study

Steenbergen, P. J., Richardson, M. K., & Champagne, D. L. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.03.025 · Cited by 230 · see citing works

Animal Models of Neuropsychiatric Disorders

Fernando, A. B. P., & Robbins, T. W. (2011) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-032210-104454 · Cited by 216 · see citing works

A Reverse-Translational Study of Dysfunctional Exploration in Psychiatric Disorders

Perry, W., Minassian, A., Paulus, M. P., Young, J. W., Kincaid, M. J., Ferguson, E. J., Henry, B. L., Zhuang, X., Masten, V. L., Sharp, R. F., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.58 · Cited by 200 · see citing works

The use of the zebrafish model in stress research

Steenbergen, P. J., Richardson, M. K., & Champagne, D. L. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.010 · Cited by 199 · see citing works

The 5-Choice Continuous Performance Test: Evidence for a Translational Test of Vigilance for Mice

Young, J. W., Light, G. A., Marston, H. M., Sharp, R. F., & Geyer, M. A. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004227 · Cited by 185 · see citing works

Identifying fast-onset antidepressants using rodent models

Ramaker, M. J., & Dulawa, S. C. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.36 · Cited by 181 · see citing works

Histopathologic characterization of the BTBR mouse model of autistic-like behavior reveals selective changes in neurodevelopmental proteins and adult hippocampal neurogenesis

Stephenson, D. T., O'Neill, S. M., Narayan, S., Tiwari, A., Arnold, E., Samaroo, H. D., Du, F., Ring, R. H., Campbell, B., Pletcher, M., et al. (2011) · Molecular Autism · doi:10.1186/2040-2392-2-7 · Cited by 180 · see citing works

Irritable bowel syndrome: towards biomarker identification

Clarke, G. A., Quigley, E. M. M., Cryan, J. F., & Dinan, T. G. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.08.001 · Cited by 180 · see citing works

Reduced expression of glutamate transporters vGluT1, EAAT2 and EAAT4 in learned helpless rats, an animal model of depression

Zink, M., Vollmayr, B., Gebicke-Haerter, P. J., & Henn, F. A. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.09.005 · Cited by 177 · see citing works

Translational Mouse Models of Autism: Advancing Toward Pharmacological Therapeutics

Kazdoba, T. M., Leach, P. T., Yang, M., Silverman, J. L., Solomon, M., & Crawley, J. N. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5003 · Cited by 172 · see citing works

Cognitive function during nicotine withdrawal: Implications for nicotine dependence treatment

Ashare, R. L., Falcone, M., & Lerman, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.04.034 · Cited by 170 · see citing works

Circadian rhythms and depression: Human psychopathology and animal models

Kronfeld-Schor, N., & Einat, H. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.020 · Cited by 166 · see citing works

Assessing learning and memory in pigs

Gieling, E. T., Nordquist, R. E., & van der Staay, F. J. (2011) · Animal Cognition · doi:10.1007/s10071-010-0364-3 · Cited by 154 · see citing works

Mapping anhedonia-specific dysfunction in a transdiagnostic approach: an ALE meta-analysis

Zhang, B., Lin, P., Shi, H., Öngür, D., Auerbach, R. P., Wang, X., Yao, S., & Wang, X. (2016) · Brain Imaging and Behavior · doi:10.1007/s11682-015-9457-6 · Cited by 152 · see citing works

Economic demand predicts addiction-like behavior and therapeutic efficacy of oxytocin in the rat

Bentzley, B. S., Jhou, T. C., & Aston‐Jones, G. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406324111 · Cited by 151 · see citing works

New Insights into Toxicity and Drug Testing

Gowder, S. J. (2013) · InTech eBooks · doi:10.5772/55886 · Cited by 149 · see citing works

The Free-movement pattern Y-maze: A cross-species measure of working memory and executive function

Cleal, M., Fontana, B. D., Ranson, D. C., McBride, S. D., Swinny, J. D., Redhead, E. S., & Parker, M. O. (2020) · Behavior Research Methods · doi:10.3758/s13428-020-01452-x · Cited by 147 · see citing works

Rodent tests of depression and anxiety: Construct validity and translational relevance

Gencturk, S., & Unal, G. (2024) · Cognitive, Affective, & Behavioral Neuroscience · doi:10.3758/s13415-024-01171-2 · Cited by 138 · see citing works

The lonely mouse: Verification of a separation-induced model of depression in female mice

Martin, A. L., & Brown, R. E. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.10.006 · Cited by 147 · see citing works

Translating cognition from animals to humans

Keeler, J. F., & Robbins, T. W. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.12.028 · Cited by 137 · see citing works

Translational assessment of reward and motivational deficits in psychiatric disorders

Der-Avakian, A., Barnes, S. A., Markou, A., & Pizzagalli, D. A. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5004 · Cited by 122 · see citing works

Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders

Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132 · see citing works

Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits

D’Souza, M. S., & Markou, A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.044 · Cited by 121 · see citing works

Developing treatments for cognitive deficits in schizophrenia: The challenge of translation

Young, J. W., & Geyer, M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114555252 · Cited by 110 · see citing works

Modelling depression in animals: at the interface of reward and stress pathways

Slattery, D. A., & Cryan, J. F. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4552-6 · Cited by 110 · see citing works

Mouse social stress induces increased fear conditioning, helplessness and fatigue to physical challenge together with markers of altered immune and dopamine function

Azzinnari, D., Sigrist, H., Staehli, S., Palme, R., Hildebrandt, T., Leparc, G., Hengerer, B., Seifritz, E., & Pryce, C. R. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.05.039 · Cited by 106 · see citing works

Developmental rodent models of fear and anxiety: from neurobiology to pharmacology

Ganella, D. E., & Kim, J. H. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12643 · Cited by 107 · see citing works

Neural Substrates of Psychostimulant Withdrawal-Induced Anhedonia

D’Souza, M. S., & Markou, A. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_20 · Cited by 107 · see citing works

Innovative Drugs to Treat Depression: Did Animal Models Fail to Be Predictive or Did Clinical Trials Fail to Detect Effects?

Belzung, C. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.342 · Cited by 106 · see citing works

Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome?

Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102 · see citing works

Neuroimaging in Psychiatric Disorders

Masdeu, J. C. (2011) · Neurotherapeutics · doi:10.1007/s13311-010-0006-0 · Cited by 104 · see citing works

Assessment of reward responsiveness in the response bias probabilistic reward task in rats: implications for cross-species translational research

Der-Avakian, A., D'Souza, M. S., Pizzagalli, D. A., & Markou, A. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.74 · Cited by 100 · see citing works

Behavioral Indices in Antipsychotic Drug Discovery

Porsolt, R. D., Moser, P. C., & Castagné, V. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.166710 · Cited by 100 · see citing works

Challenges in the Search for Drugs to Treat Central Nervous System Disorders

Enna, S. J., & Williams, M. C. (2009) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.143420 · Cited by 100 · see citing works

A novel 3D method of locomotor analysis in adult zebrafish: Implications for automated detection of CNS drug-evoked phenotypes

Stewart, A., Grieco, F., Tegelenbosch, R. A. J., Kyzar, E. J., Nguyen, M., Kaluyeva, A. A., Song, C., Noldus, L. P. J. J., & Kalueff, A. V. (2015) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2015.07.023 · Cited by 99 · see citing works

Social stress models in depression research: what do they tell us?

Chaouloff, F. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1606-x · Cited by 99 · see citing works

Behavioral profiling as a translational approach in an animal model of posttraumatic stress disorder.

Ardi, Z., Albrecht, A., Richter-Levin, A., Saha, R., & Richter-Levin, G. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.01.012 · Cited by 83 · see citing works

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

Smith, S. M., Uslaner, J. M., Cox, C. D., Huszar, S. L., Cannon, C. E., Vardigan, J. D., Eddins, D. M., Toolan, D. M., Kandebo, M., Yao, L., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.06.013 · Cited by 86 · see citing works

The Ups and Downs of Modelling Mood Disorders in Rodents

Slattery, D. A., & Cryan, J. F. (2014) · ILAR Journal · doi:10.1093/ilar/ilu026 · Cited by 85 · see citing works

Association Between Nicotine Withdrawal and Reward Responsiveness in Humans and Rats

Pergadia, M. L., Der‐Avakian, A., D’Souza, M. S., Madden, P. A. F., Heath, A. C., Shiffman, S. M., Markou, A., & Pizzagalli, D. A. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.1016 · Cited by 85 · see citing works

Schedule-induced polydipsia as a model of compulsive behavior: neuropharmacological and neuroendocrine bases

Moreno, M., & Flores, P. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2570-3 · Cited by 85 · see citing works

Transgenic mouse models for ADHD

Leo, D., & Gainetdinov, R. (2013) · Cell and Tissue Research · doi:10.1007/s00441-013-1639-1 · Cited by 74 · see citing works

Toward the explainability, transparency, and universality of machine learning for behavioral classification in neuroscience

Goodwin, N. L., Nilsson, S. R. O., Choong, J. J., & Golden, S. A. (2022) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2022.102544 · Cited by 84 · see citing works

Developing highER-throughput zebrafish screens for in-vivo CNS drug discovery

Stewart, A., Gerlai, R. T., & Kalueff, A. V. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00014 · Cited by 82 · see citing works

Measuring the construct of executive control in schizophrenia: defining and validating translational animal paradigms for discovery research.

Gilmour, G., Arguello, A., Bari, A., Brown, V., Carter, C., Floresco, S., Jentsch, D., Tait, D. S., Young, J., & Robbins, T. (2013) · Neuroscience and Biobehavioral Reviews · doi:10.1016/j.neubiorev.2012.04.006 · Cited by 91 · see citing works

How Many Ways Can Mouse Behavioral Experiments Go Wrong? Confounding Variables in Mouse Models of Neurodegenerative Diseases and How to Control Them

Schellinck, H. M., Cyr, D. P., & Brown, R. E. (2010) · Advances in the study of behavior · doi:10.1016/s0065-3454(10)41007-4 · Cited by 77 · see citing works

The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action

Wong, E. H. F., Tarazi, F. I., & Shahid, M. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.02.001 · Cited by 75 · see citing works

Measuring behavior of animal models: faults and remedies

Fonio, E., Golani, I., & Benjamini, Y. (2012) · Nature Methods · doi:10.1038/nmeth.2252 · Cited by 75 · see citing works

Validating Animal Models for Preclinical Research: A Scientific and Ethical Discussion

Varga, O., Hansen, A. K., Sandøe, P., & Olsson, I. A. S. (2010) · Alternatives to Laboratory Animals · doi:10.1177/026119291003800309 · Cited by 74 · see citing works

CRISPR/Cas9-mediated disruption of SHANK3 in monkey leads to drug-treatable autism-like symptoms

Tu, Z., Zhao, H., Li, B., Yan, S., Wang, L., Tang, Y., Li, Z., Bai, D., Li, C., Lin, Y., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy367 · Cited by 73 · see citing works

Future Directions for Research in Autism Spectrum Disorders

Damiano, C. R., Mazefsky, C. A., White, S. W., & Dichter, G. S. (2014) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2014.945214 · Cited by 76 · see citing works

Are animal models of addiction useful?

Field, M., & Kersbergen, I. (2019) · Addiction · doi:10.1111/add.14764 · Cited by 69 · see citing works

Low Doses of Psilocybin and Ketamine Enhance Motivation and Attention in Poor Performing Rats: Evidence for an Antidepressant Property

Higgins, G. A., Carroll, N. K., Brown, M., MacMillan, C., Silenieks, L. B., Thevarkunnel, S., Izhakova, J., Magomedova, L., DeLannoy, I., & Sellers, E. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.640241 · Cited by 70 · see citing works

Encore: Behavioural animal models of stress, depression and mood disorders

Petković, A., & Chaudhury, D. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.931964 · Cited by 70 · see citing works

Investigating the mechanism(s) underlying switching between states in bipolar disorder

Young, J. W., & Dulcis, D. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.019 · Cited by 68 · see citing works

Oxytocin and Rodent Models of Addiction

Leong, K.-C., Cox, S. S., King, C. E., Becker, H. C., & Reichel, C. M. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.007 · Cited by 69 · see citing works

Haloperidol‐induced catalepsy as an animal model for parkinsonism: A systematic review of experimental studies

Waku, I., Magalhães, M. S., Alves, C. D. O., & de Oliveira, A. R. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15222 · Cited by 67 · see citing works

Short-term social isolation induces depressive-like behaviour and reinstates the retrieval of an aversive task: mood-congruent memory in male mice?

Takatsu-Coleman, A. L., Patti, C. L., Zanin, K. A., Zager, A., Carvalho, R. C., Borçoi, A. R., Ceccon, L. M. B., Berro, L. F., Tufik, S., Andersen, M. L., et al. (2013) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.120050 · Cited by 66 · see citing works

Stress and glucocorticoid receptor transcriptional programming in time and space: Implications for the brain–gut axis

Wiley, J. W., Higgins, G. A., & Athey, B. D. (2015) · Neurogastroenterology & Motility · doi:10.1111/nmo.12706 · Cited by 65 · see citing works

Preclinical Behavioral Models for Predicting Antipsychotic Activity

Castagné, V., Moser, P. C., & Porsolt, R. D. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57010-4 · Cited by 64 · see citing works

Relaxin’ the brain: a case for targeting the nucleus incertus network and relaxin‐3/RXFP3 system in neuropsychiatric disorders

Kumar, J. R., Rajkumar, R., Jayakody, T., Marwari, S., Hóng, J., Ma, S., Gundlach, A. L., Lai, M. K. P., & Dawe, G. S. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13564 · Cited by 62 · see citing works

Relationship between effortful motivation and neurocognition in schizophrenia

Bismark, A. W., Thomas, M. L., Tarasenko, M. A., Shiluk, A. L., Rackelmann, S. Y., Young, J. W., & Light, G. A. (2017) · Schizophrenia Research · doi:10.1016/j.schres.2017.06.042 · Cited by 63 · see citing works

Behavioral assessment of neuropathic pain, fatigue, and anxiety in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy

Grace, P. M., Loram, L. C., Christianson, J. P., Strand, K. A., Flyer-Adams, J. G., Penzkover, K. R., Forsayeth, J., van Dam, A., Mahoney, M. J., Maier, S. F., et al. (2016) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.05.012 · Cited by 62 · see citing works

The role of fMRI in drug development

Carmichael, O. T., Schwarz, A. J., Chatham, C. H., Scott, D., Turner, J. A., Upadhyay, J., Coimbra, A., Goodman, J. A., Baumgartner, R., English, B. A., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.11.012 · Cited by 60 · see citing works

5-hydroxytryptamine 2C receptors in the dorsal striatum mediate stress-induced interference with negatively reinforced instrumental escape behavior

Strong, P. V., Christianson, J. P., Loughridge, A. B., Amat, J., Maier, S. F., Fleshner, M., & Greenwood, B. N. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.041 · Cited by 61 · see citing works

Using zebrafish (Danio rerio) models to understand the critical role of social interactions in mental health and wellbeing

Fontana, B. D., Müller, T. E., Cleal, M., de Abreu, M. S., Norton, W., Demin, K. A., Amstislavskaya, T. G., Petersen, E. V., Kalueff, A. V., Parker, M. O., et al. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.101993 · Cited by 61 · see citing works

The translational study of apathy—an ecological approach

Cathomas, F., Hartmann-Riemer, M. N., Seifritz, E., Pryce, C. R., & Kaiser, S. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00241 · Cited by 61 · see citing works

Anhedonia, avolition, and anticipatory deficits: Assessments in animals with relevance to the negative symptoms of schizophrenia

Barnes, S. A., Der‐Avakian, A., & Markou, A. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.001 · Cited by 60 · see citing works

The failure of the antidepressant drug discovery process is systemic

Hendrie, C. A., & Pickles, A. R. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112466185 · Cited by 58 · see citing works

Lost in Translation: Neuropsychiatric Drug Development

Becker, R. E., & Greig, N. H. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000446 · Cited by 58 · see citing works

CRISPR/Cas9 mediated generation of an ovine model for infantile neuronal ceroid lipofuscinosis (CLN1 disease)

Eaton, S. L., Proudfoot, C., Lillico, S. G., Skehel, P., Kline, R., Hamer, K., Rzechorzek, N. M., Clutton, E. R., Gregson, R., King, T., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-45859-9 · Cited by 55 · see citing works

Caution When Diagnosing Your Mouse With Schizophrenia: The Use and Misuse of Model Animals for Understanding Psychiatric Disorders

Wong, A. H. C., & Josselyn, S. A. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.023 · Cited by 55 · see citing works

Animal models of tic disorders: A translational perspective

Godar, S. C., Mosher, L. J., Giovanni, G. D., & Bortolato, M. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.09.008 · Cited by 54 · see citing works

The role of translational bioinformatics in drug discovery

Buchan, N. S., Rajpal, D. K., Webster, Y., Alatorre, C., Gudivada, R. C., Zheng, C., Sanséau, P., & Koehler, J. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.03.002 · Cited by 53 · see citing works

Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window

Mihov, Y., & Hasler, G. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw002 · Cited by 54 · see citing works

The utility of patient specific induced pluripotent stem cells for the modelling of Autistic Spectrum Disorders

Cocks, G. D., Curran, S. R., Gami‐Patel, P., Uwanogho, D., Jeffries, A. R., Kathuria, A., Lucchesi, W., Wood, V. H. J., Dixon, R., Ogilvie, C. M., et al. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3196-4 · Cited by 49 · see citing works

Novel positive allosteric modulators of GABAA receptors: Do subtle differences in activity at α1 plus α5 versus α2 plus α3 subunits account for dissimilarities in behavioral effects in rats?

Savić, M. M., Majumder, S., Huang, S., Edwankar, R. V., Furtmüller, R., Joksimovic, S. M., Clayton, T., Ramerstorfer, J., Milinković, M. M., Roth, B. L., et al. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.01.004 · Cited by 51 · see citing works

Putative cognitive enhancers in preclinical models related to schizophrenia: The search for an elusive target

Barak, S., & Weiner, I. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.03.011 · Cited by 50 · see citing works

Interoception and Learning: Import to Understanding and Treating Diseases and Psychopathologies

Bevins, R. A., & Besheer, J. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn5001028 · Cited by 49 · see citing works

Recent Progress in the Synthesis and Characterization of Group II Metabotropic Glutamate Receptor Allosteric Modulators

Sheffler, D. J., Pinkerton, A. B., Dahl, R. S., Markou, A., & Cosford, N. D. P. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200008d · Cited by 49 · see citing works

Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System

Srinivas, N., Maffuid, K., & Kashuba, A. D. M. (2018) · Clinical Pharmacokinetics · doi:10.1007/s40262-018-0632-y · Cited by 49 · see citing works

Touchscreen cognitive testing: Cross-species translation and co-clinical trials in neurodegenerative and neuropsychiatric disease

Palmer, D. D., Dumont, J. R., Dexter, T. D., Prado, M. A. M., Finger, E. C., Bussey, T. J., & Saksida, L. M. (2021) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2021.107443 · Cited by 52 · see citing works

Value of Animal Models for Predicting CNS Therapeutic Action

McArthur, R. A. (2010) · Elsevier eBooks · doi:10.1016/b978-0-08-045396-5.00021-x · Cited by 8 · see citing works

Conventional Behavioral Models and Readouts in Drug Discovery: The Importance of Improving Translation

Rutten, K. (2021) · Modern CNS Drug Discovery · doi:10.1007/978-3-030-62351-7_5 · Cited by 1 · see citing works

Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development

Kaffman, A., White, J. D., Wei, L., Johnson, F. K., & Krystal, J. H. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_1 · Cited by 31 · see citing works

True alignment of preclinical and clinical research to enhance success in CNS drug development: a review of the current evidence

Goetghebeur, P., & Swartz, J. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116645269 · Cited by 22 · see citing works

Animal and translational models for CNS drug discovery

McArthur, R. A. (2008) · Cited by 2 · see citing works